EUCTR2005-004517-14-DE进行中（未招募）不适用
Open study to determine the immunogenicity and reactogenicity of Influsplit SSW 2005/2006 in children from 6 years until 13 years of age - Flu-062
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Healthy children or children with underlying disease aged from 6 to 13 years
- •2. Only children, which were never vaccinated before or have never experienced a confirmed influenza before, can be enrolled
- •3. Written informed consent obtained by the parents
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •4. Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceeding the vaccination, or planned use during the study period
- •5. Acute disease at the time of enrolment
- •6. History of allergic disease or reactions
研究者
相似试验
进行中（未招募）
不适用
Study to evaluate the immunogenicity, safety, and reactogenicity of TWINRIX ADULT containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years.EUCTR2015-001516-35-Outside-EU/EEAGlaxoSmithKline Biologicals178
进行中（未招募）
不适用
Study to evaluate immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ Inactivated Polio Vaccine (Poliorix) in healthy Chinese toddlers.Booster immunisation of healthy children in the second year of life against poliomyelitis.EUCTR2012-004513-14-Outside-EU/EEAGlaxoSmithKline Biologicals957
进行中（未招募）
不适用
Immunogenicity and safety study of booster dose of GSK Biologicals’ IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) vaccine.Booster immunisation of healthy children in the second year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.EUCTR2012-003324-20-Outside-EU/EEAGlaxoSmithKline Biologicals831
进行中（未招募）
不适用
Immunogenicity and safety study of GSK Biologicals’ Infanrix-IPV+Hib™ vaccine.Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases.EUCTR2011-005868-25-Outside-EU/EEAGlaxoSmithKline Biologicals985
进行中（未招募）
不适用
Study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ inactivated polio vaccine (Poliorix) in infants.Primary immunisation of healthy infants in the first year of life against poliomyelitisEUCTR2011-003167-30-Outside-EU/EEAGlaxoSmithKline Biologicals1,101